Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study
Aim of investigation. Comparative assessment of efficacy and safety of Pegaltevir and PegIntron in within pattern of combined antiviral therapy in previously untreated patients with chronic hepatitis C.Material and methods. Overall 140 patients with chronic hepatitis C, who received no antiviral the...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2014-07-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1090 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860187562246144 |
|---|---|
| author | V. T. Ivashkin Ye. N. Bessonova P. O. Bogomolov N. I. Geyvandova K. V. Zhdanov M. V. Mayevskaya V. G. Morozov V. D. Pasechnikov I. Yu. Khomenko A. V. Yagoda |
| author_facet | V. T. Ivashkin Ye. N. Bessonova P. O. Bogomolov N. I. Geyvandova K. V. Zhdanov M. V. Mayevskaya V. G. Morozov V. D. Pasechnikov I. Yu. Khomenko A. V. Yagoda |
| author_sort | V. T. Ivashkin |
| collection | DOAJ |
| description | Aim of investigation. Comparative assessment of efficacy and safety of Pegaltevir and PegIntron in within pattern of combined antiviral therapy in previously untreated patients with chronic hepatitis C.Material and methods. Overall 140 patients with chronic hepatitis C, who received no antiviral therapy previously were included in original study. Patients were randomized in 4 groups. Groups differed in relation to received drug and hepatitis C virus genotype. All patients received 1,5 mkg per 1 kg body weight per week of Pegaltevir or PegIntron and 800–1400 mg of ribavirin per day. Preliminary estimation of drug efficacy was based on rates of rapid and early virologic response (RVR and EVR) achievement, dynamics of biochemical tests, dynamics of blood level of peginterferon alpha and neopterin. Safety features were estimated as well.Results. Comparative analysis has demonstrated absence of statistically significant distinctions of RVR and РВО rates at application of two peginterferon alpha-2b drugs. There were no differences in frequency of achievement of serologic response, as well as safety in Pegaltevir and PegIntron groups. Dynamics of blood concentration of peginterferon alpha correlated to neopterin concentration both in Pegaltevir group and in PegIntron group.Conclusions. Study results have shown high rates of RVR and РВО achievement, and acceptable safety profile of Pegaltevir, comparable with that of PegIntron at chronic hepatitis C in previously untreated patients. |
| format | Article |
| id | doaj-art-3e6f26b307e24d84922bfe50e97f41bc |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2014-07-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-3e6f26b307e24d84922bfe50e97f41bc2025-02-10T16:14:33ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732014-07-012414755691Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical studyV. T. Ivashkin0Ye. N. Bessonova1P. O. Bogomolov2N. I. Geyvandova3K. V. Zhdanov4M. V. Mayevskaya5V. G. Morozov6V. D. Pasechnikov7I. Yu. Khomenko8A. V. Yagoda9State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationGovernment healthcare institution «Sverdlovsk regional clinical hospital N 1»LLC «Tsentrosoyuz Clinical hospital»Stavropol region State government-financed healthcare institution «Stavropol regional clinical center of specialized medical care»State military educational government-financed institution of higher professional education «Kirov military medical academy» Ministry of Defense of the Russian FederationState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationLLC «Hepatologist» medical companyState educational government-financed institution of higher professional education «Stavropol state medical university » Ministry of Healthcare of the Russian FederationMunicipal health care institution «Semashko City hospital N 1Stavropol region State government-financed healthcare institution «Stavropol regional clinical center of specialized medical care»Aim of investigation. Comparative assessment of efficacy and safety of Pegaltevir and PegIntron in within pattern of combined antiviral therapy in previously untreated patients with chronic hepatitis C.Material and methods. Overall 140 patients with chronic hepatitis C, who received no antiviral therapy previously were included in original study. Patients were randomized in 4 groups. Groups differed in relation to received drug and hepatitis C virus genotype. All patients received 1,5 mkg per 1 kg body weight per week of Pegaltevir or PegIntron and 800–1400 mg of ribavirin per day. Preliminary estimation of drug efficacy was based on rates of rapid and early virologic response (RVR and EVR) achievement, dynamics of biochemical tests, dynamics of blood level of peginterferon alpha and neopterin. Safety features were estimated as well.Results. Comparative analysis has demonstrated absence of statistically significant distinctions of RVR and РВО rates at application of two peginterferon alpha-2b drugs. There were no differences in frequency of achievement of serologic response, as well as safety in Pegaltevir and PegIntron groups. Dynamics of blood concentration of peginterferon alpha correlated to neopterin concentration both in Pegaltevir group and in PegIntron group.Conclusions. Study results have shown high rates of RVR and РВО achievement, and acceptable safety profile of Pegaltevir, comparable with that of PegIntron at chronic hepatitis C in previously untreated patients.https://www.gastro-j.ru/jour/article/view/1090chronic hepatitis ctreatmentpeginterferon alpha-2bpegaltevir |
| spellingShingle | V. T. Ivashkin Ye. N. Bessonova P. O. Bogomolov N. I. Geyvandova K. V. Zhdanov M. V. Mayevskaya V. G. Morozov V. D. Pasechnikov I. Yu. Khomenko A. V. Yagoda Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study Российский журнал гастроэнтерологии, гепатологии, колопроктологии chronic hepatitis c treatment peginterferon alpha-2b pegaltevir |
| title | Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study |
| title_full | Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study |
| title_fullStr | Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study |
| title_full_unstemmed | Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study |
| title_short | Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study |
| title_sort | efficacy and safety of the first domestic pegilated interferon alpha 2b pegaltevir at chronic hepatitis c pilot data of phase iii clinical study |
| topic | chronic hepatitis c treatment peginterferon alpha-2b pegaltevir |
| url | https://www.gastro-j.ru/jour/article/view/1090 |
| work_keys_str_mv | AT vtivashkin efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT yenbessonova efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT pobogomolov efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT nigeyvandova efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT kvzhdanov efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT mvmayevskaya efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT vgmorozov efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT vdpasechnikov efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT iyukhomenko efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy AT avyagoda efficacyandsafetyofthefirstdomesticpegilatedinterferonalpha2bpegalteviratchronichepatitiscpilotdataofphaseiiiclinicalstudy |